Document is current
Any future updates will be listed below
-
Authors
Alver, Maris
Palover, Marili
Saar, Aet
Läll, Kristi
Zekavat, Seyedeh Maryam
Tõnisson, Neeme
Leitsalu, Liis
Reigo, Anu
Nikopensius, Tiit
Ainla, Tiia
Kals, Mart
Mägi, Reedik
Gabriel, Stacey B.
Eha, Jaan
Lander, Eric S.
Irs, Alar
Philippakis, Anthony
Marandi, Toomas
Natarajan, Pradeep
Metspalu, Andres
Kathiresan, Sekar
Esko, Tõnu
- License Information
-
More Information
Article History
Received: 22 June 2018
Accepted: 6 September 2018
First Online: 1 October 2018
Disclosure
: A.P. is a Venture Partner at GV, which is part of Alphabet Corporation; in that capacity he receives monetary compensation. S.K. has received grants and personal fees from Bayer and Amarin Pharma, Inc.; compensation as a member of the scientific advisory board from Catabasis, Regeneron Genetics Center, Merck, Celera, GENOMICS plc, Corvidia Therapeutics, Novo Ventures; and is affiliated with and received compensation from San Therapeutics, Novartis, AstraZeneca, Alynlam, Eli Lilly, Leerink Partners, Noble Insights, Ionis, Haug Partners LLC, Genetic Modifiers Newco Inc., Morgan Stanley Institutional Equity Division, ExpertConnect. Additionally, S.K. has a patent number WO2016086197 “Method of identifying and treating a person having predisposition to or afflicted with a cardiometabolic disease” issued. The other authors declare no conflicts of interest.
